Paper
A critical evaluation of the mechanisms of action proposed for the antitumor effects of the anthracycline antibiotics adriamycin and daunorubicin.
Published Apr 1, 1999 · D. Gewirtz
Biochemical pharmacology
Q1 SJR score
2,120
Citations
101
Influential Citations
Abstract
Abstract hidden due to publisher request; this does not indicate any issues with the research. Click the full text link above to read the abstract and view the original source.
Highly CitedStudy Snapshot
The anthracycline antibiotics doxorubicin and daunorubicin may inhibit tumor growth through DNA synthesis inhibition, free radical formation, and lipid peroxidation, with potential side effects including cardiotoxicity.
PopulationOlder adults (50-71 years)
Sample size24
MethodsObservational
OutcomesBody Mass Index projections
ResultsSocial networks mitigate obesity in older groups.
Sign up to use Study Snapshot
Consensus is limited without an account. Create an account or sign in to get more searches and use the Study Snapshot.
Full text analysis coming soon...
References
Anthracycline antibiotic blockade of SV40 T antigen helicase action.
Anthracycline antibiotics effectively block SV40 T antigen helicase action, potentially contributing to their cytotoxic and anti-cancer activities.
1998·17citations·N. Bachur et al.·Biochemical pharmacology
Biochemical pharmacology
p16INK4A Participates in a G1 Arrest Checkpoint in Response to DNA Damage
p16 INK4A plays a role in a G1 arrest checkpoint in response to DNA damage, potentially preventing tumor progression by preventing cells with wild-type Rb from bypassing this checkpoint.
1998·168citations·G. Shapiro et al.·Molecular and Cellular Biology
Molecular and Cellular Biology
Influence of ionizing radiation on proliferation, c-myc expression and the induction of apoptotic cell death in two breast tumour cell lines differing in p53 status.
In the absence of classical apoptotic cell death, radiosensitivity is not predictably related to the p53 status of the cell, and neither p53 nor c-myc are essential for growth arrest in response to ionizing radiation.
1997·41citations·N. C. Watson et al.·International journal of radiation biology
International journal of radiation biology
Inhibition of DNA unwinding and ATPase activities of human DNA helicase II by chemotherapeutic agents.
Ethidium bromide, actinomycin C1, daunorubicin, and nogalamycin inhibit DNA unwinding and ATPase activities of human DNA helicase II, potentially impairing their antitumor effects by binding to DNA.
1997·60citations·N. Tuteja et al.·Biochemical and biophysical research communications
Biochemical and biophysical research communications
Factors affecting topotecan-induced programmed cell death: adhesion protects cells from apoptosis and impairs cleavage of poly(ADP-ribose)polymerase.
Cell attachment and attachment status significantly influence the sensitivity to topotecan-induced programmed cell death, with attachment to ProNectin F protecting cells from apoptosis and cleavage of PARP.
1997·45citations·C. Whitacre et al.·Cancer research
Cancer research
Citations
Chemotherapy alone versus chemotherapy plus radiotherapy for adults with early-stage Hodgkin's lymphoma.
Additional radiotherapy may slightly improve progression-free survival in adults with early-stage Hodgkin's lymphoma, but overall survival and adverse events data are inconclusive.
2024·0citations·M. Goldkuhle et al.·The Cochrane database of systematic reviews
The Cochrane database of systematic reviews
Enhancing chemosensitivity and reducing cancer stem-like cell population using doxorubicin-loaded polyelectrolyte nanocapsules
Doxorubicin-loaded polyelectrolyte nanocapsules with hyaluronic acid and protamine can enhance chemosensitivity and reduce cancer stem-like cell population in breast cancer treatment.
2024·0citations·Sreeranjini Pulakkat et al.·Journal of Drug Delivery Science and Technology
Journal of Drug Delivery Science and Technology
Impact of Vitamin D Levels on Progression-Free Survival and Response to Neoadjuvant Chemotherapy in Breast Cancer Patients: A Systematic Review and Meta-Analysis
Adequate vitamin D levels are associated with a 22% reduction in non-response to neoadjuvant chemotherapy and a 35% reduction in disease progression in breast cancer patients.
2024·0citations·A. Ottaiano et al.·Cancers
Cancers
Evolution of Theories on Doxorubicin-Induced Late Cardiotoxicity-Role of Topoisomerase
Doxorubicin-induced late cardiotoxicity can be explained by mechanisms related to topoisomerase 2 (Top2), including oxidative stress and redox balance regulation.
2024·0citations·Jarosław Szponar et al.·International Journal of Molecular Sciences
International Journal of Molecular Sciences
Disrupted Lipid Metabolism, Cytokine Signaling, and Dormancy: Hallmarks of Doxorubicin-Resistant Triple-Negative Breast Cancer Models
Doxorubicin-resistant triple-negative breast cancer cells enter a dormant-like state, slow growth, and activate survival pathways, suggesting new treatment approaches could improve chemotherapy effectiveness and patient outcomes.
2024·0citations·Radhakrishnan Vishnubalaji et al.·Cancers
Cancers
High-throughput expansion microscopy enables scalable super-resolution imaging
High-throughput expansion microscopy (HiExM) enables scalable super-resolution imaging of single cells in 96-well plates, improving detection of cellular phenotypes in response to drug treatment.
2024·0citations·John H. Day et al.·eLife
eLife
Ratio type nanoprobe with boric acid as recognition unit for imaging intracellular H2O2 with SERS.
The novel SERS nanoprobe with boric acid as recognition unit accurately detects and quantifies intracellular H2O2 levels in living cells, aiding in monitoring and analyzing cell apoptosis and growth processes.
2024·0citations·Yizhuo Tian et al.·Talanta
Talanta
An Electrochemical Biosensor Analysis of the Interaction of a Two-Vector Phospholipid Composition of Doxorubicin with dsDNA and Breast Cancer Cell Models In Vitro
Cell-based biosensors can effectively analyze the interaction between doxorubicin and breast cancer cell lines, aiding in the discovery of new anticancer medicinal preparations.
2024·0citations·L. Kostryukova et al.·Pharmaceutics
Pharmaceutics